Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model

Journal of Investigative Dermatology

Volumn 130, Issue 2, 2010, Pages 455-463

  Rosada, Cecilia ^a   Stenderup, Karin ^a   De Darkó, Elisabeth ^b   Dagnaes Hansen, Frederik ^c   Kamp, Søren ^d   Dam, Tomas Norman ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Valderm ApS   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; VALRUBICIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; EPIDERMIS CELL; HUMAN; HUMAN TISSUE; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REMISSION; XENOGRAFT;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; EPIDERMIS; HUMANS; KERATINOCYTES; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PSORIASIS; URINARY BLADDER NEOPLASMS;

EID: 75549084492     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.277     Document Type: Article

References (42)

1. Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL et al. (2002) Novel extranuclear-targeted anthracyclines override the anti-apoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther 1:469-481
2. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC et al. (1989) DNA topoisomerase II-mediated interaction of doxorubicin and daunor-ubicin congeners with DNA. Cancer Res 49:5969-5978
3. Bonadonna G, Monfardini S, De LM, Fossati-Bellani F (1969) Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J 3:503-506
4. Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5:699-711
5. Burke TG, Israel M, Seshadri R, Doroshow JH (1989) A fluorescence study examining how 14-valerate side chain substitution modulates anthracy-cline binding to small unilamellar phospholipid vesicles. Biochim Biophys Acta 982:123-130
6. Burke TG, Israel M, Seshadri R, Doroshow JH (1990) Abrogation of the selectivity of adriamycin for negatively-charged phospholipids by 14-valerate side chain substitution. Cancer Biochem Biophys 11:177-185
7. Chuang LF, Kung HF, Israel M, Chuang RY (1992) Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochem Pharmacol 43: 865-872
8. Chuang RY, Chuang LF, Kawahata RT, Israel M (1983) Effect of N-trifluoroacetyladriamycin-14-valerate on [3H]thymidine uptake and DNA synthesis of human lymphoma cells. J Biol Chem 258:1062-1065
9. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ (1999) 1alpha,25-Dihydroxycho- lecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 113:1082-1089
10. Dantchev D, Balercia G, Bourut C, Anjo A, Maral R, Mathe G (1984) Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs. Biomed Pharmacother 38:322-328
11. Dantchev D, Slioussartchouk V, Paintrand M, Bourut C, Hayat M, Mathe G (1980) Ultrastructural study of the cardiotoxicity and light-microscopic findings of the skin after treatment of golden hamsters with seven different anthracyclines. Recent Results Cancer Res 74:223-249
12. Denning MF (2004) Epidermal keratinocytes: regulation of multiple cell phenotypes by multiple protein kinase C isoforms. Int J Biochem Cell Biol 36:1141-1146
13. Di Marco A, Gaetani M, Scarpinato B (1969) Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep 53:33-37
14. Duffin KC, Chandran V, Gladman DD, Krueger GG, Elder JT, Rahman P (2008) Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 35:1449-1453
15. Duffin KC, Krueger GG (2009) Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol 129:827-833
16. Facchinetti T, Raz A, Goldman R (1978) A differential interaction of daunomycin, adriamycin, and N-trifluoroacetyladriamycin 14-valerate with mouse peritoneal macrophages. Cancer Res 38:3944-3949
17. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A (2007) Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9:461-467
18. Greenberg RE, Bahnson RR, Wood D, Childs SJ, Bellingham C, Edson M et al. (1997) Initial report on intravesical administration of N-trifluoroacetyla- driamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 49:471-475
19. Israel M, Modest EJ, Frei E III (1975) N-trifluoroacetyladriamycin-14- valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 35:1365-1368
20. Kanter PM, Schwartz HS (1979) Effects of N-trifluoroacetyladriamycin-14- valerate and related agents on DNA strand damage and thymidine incorporation in CCRF-CEM cells. Cancer Res 39:448-451
21. Kligman MA, Christophers E (1963) Preparation of isolated sheets of human stratum corneum. Arch Dermatol 88:702-705
22. Krishan A, Dutt K, Israel M, Ganapathi R (1981) Comparative effects of adriamycin and N-trifluoroacetyladriamycin-14-valerate on cell kinetics, chromosomal damage, and macromolecular synthesis in vitro. Cancer Res 41:2745-2750
23. Krishan A, Israel M, Modest EJ, Frei E III (1976) Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14- valerate. Cancer Res 36:2108-2109
24. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L et al. (2008) Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 181:4733-4741
25. Lothstein L, Israel M, Sweatman TW (2001) Anthracycline drug targeting: cytoplasmic versus nuclear\-a fork in the road. Drug Resist Updat 4:169-177
26. Lothstein L, Rodrigues PJ, Sweatman TW, Israel M (1998) Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anticancer Drugs 9:58-66
27. Masquelier M, Vitols S, Peterson C (1986) Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res 46:3842-3847
28. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229
29. Niell HB, Hunter RF, Herrod HG, Israel M (1987) Effects of N-trifluoroace-tyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines. Cancer Chemother Pharmacol 19:47-52
30. Olson RD, Headley MB, Hodzic A, Walsh GM, Wingett DG (2007) In vitro and in vivo immunosuppressive activity of a novel anthracycline, 13-deoxy, 5-iminodoxorubicin. Int Immunopharmacol 7: 734-743
31. Onrust SV, Lamb HM (1999) Valrubicin. Drugs Aging 15:69-75
32. Patterson AL, Greenberg RE, Weems L, Bahnson R, Wajsman Z, Israel M et al. (2000) Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 56:232-235
33. Pisano C, Tambaro R, Di MM, Formato R, Iaffaioli VR, Pignata S (2004) Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer. Arch Dermatol Res 296:141-142
34. Raj D, Brash DE, Grossman D (2006) Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol 126:243-257
35. Schwartz HS, Kanter PM (1981) DNA damage by anthracycline drugs in human leukemia cells. Cancer Lett 13:309-313
36. Skvara H, Dawid M, Kleyn E, Wolff B, Meingassner JG, Knight H et al. (2008) The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 118:3151-3159
37. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163:761-767 (Pubitemid 30091611)
38. Stenderup K, Rosada C, Worsaae A, Dagnaes-Hansen F, Steiniche T, Hasselager E et al. (2009) Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 160:284-296
39. Sweatman TW, Parker RF, Israel M (1991) Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclini-cal study. Cancer Chemother Pharmacol 28:1-6
40. Wani MK, Koseki Y, Yarber RH, Sweatman TW, Ahmed A, Samant S et al. (2000) Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope 110:2026-2032
41. Warren RB, Brown BC, Lavery D, Ashcroft DM, Griffiths CE (2009) Biologic therapies for psoriasis: practical experience in a UK. tertiary referral centre. Br J Dermatol 160:162-169
42. Zhao Y, Fishelevich R, Petrali JP, Zheng L, Anatolievna MA, Deng A et al. (2008) Activation of keratinocyte protein kinase C zeta in psoriasis plaques. J Invest Dermatol 128:2190-2197